Brought to you by 
Neurodegenerative start-up Denali Therapeutics nets $267.4mm in IPO
14 Dec 2017
Executive Summary
Denali Therapeutics Inc. (neurodegenerative disease drug development) netted $267.4mm in an initial public offering of 15.9mm shares (including the overallotment) at $18, the mid-point of its anticipated range. The company had originally planned to sell 8.33mm shares.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- IPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Neurodegenerative start-up Denali Therapeutics nets $267.4mm in IPO
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice